Selecta Biosciences, a clinical-stage biopharmaceutical company, is making waves in the medical field with their research and development of nanoparticle immunomodulatory drugs. These drugs have the potential to revolutionize the treatment and prevention of various human diseases. Currently, the company's lead therapeutic gene therapy program, SEL-302, is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. But that's not all - they're also developing biologic therapies such as SEL-212, which is in Phase III clinical trials for the treatment of chronic refractory gout, and product candidates to treat IgA-mediated diseases. Excitingly, Selecta Biosciences is also developing gene therapies for various autoimmune diseases, including Pompe disease, Duchenne muscular dystrophy, and lysosomal storage disorder. Moreover, the company is focusing on developing tolerogenic therapies to combat autoimmune diseases. With license and collaboration agreements from several key players in the industry, including Astellas Therapeutics and Sarepta Therapeutics, Selecta Biosciences, headquartered in Watertown, Massachusetts, is positioning itself as a major player in the biopharmaceutical industry.
Selecta Biosciences's ticker is SELB
The company's shares trade on the NASDAQ stock exchange
They are based in Watertown, Massachusetts
There are 11-50 employees working at Selecta Biosciences
It is selectabio.com
Selecta Biosciences is in the Healthcare sector
Selecta Biosciences is in the Biotechnology industry
The following five companies are Selecta Biosciences's industry peers: